Lynwood Capital Management Inc. Cingulate Inc. Transaction History

Lynwood Capital Management Inc.

  • $11.2 Million
  • Q1 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 02, 2022
SELL
$259.2 - $453.6 $58.6 Million - $103 Million
-225,994 Closed
0 $0
Q1 2022

May 05, 2022
BUY
$278.4 - $698.4 $28.1 Million - $70.5 Million
100,994 Added 80.8%
225,994 $445,000
Q4 2021

Feb 11, 2022
BUY
$556.8 - $1068.0 $69.6 Million - $134 Million
125,000 New
125,000 $345,000

About Cingulate Inc.

CING Quotes by TradingView
  • Ticker CING
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 11,309,400
  • Market Cap $42.2M
  • Description
  • Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-de...
More about CING
Track This Portfolio

Track Lynwood Capital Management Inc. Portfolio

Follow Lynwood Capital Management Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lynwood Capital Management Inc., based on Form 13F filings with the SEC.

News

Stay updated on Lynwood Capital Management Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email